CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 GlobeNewswire July 31, 2025 Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the […]